This changed particularly when a small percentage of non small cell lung cancer (NSCLC) were identified with mutations in the EGFR gene that rendered those tumors sensitive to the EGFR tyrosine kinase inhibitors (TKI) (Hirsch et al., 2003; Mok et al., 2009; Rosell et al., 2012; Sequist et al., 2013; Wu et al., 2014; Wu et al., 2017; Planchard et al., 2018; Ramalingam et al., 2020). This evidence concerns the gene EGFR and non-small cell lung carcinoma.